SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

Search

Almirall SA

Closed

SectorHealthcare

9.66 -0.1

Overview

Share price change

24h

Current

Min

9.51

Max

9.805

Key metrics

By Trading Economics

Income

-430K

-2.1M

Sales

28M

258M

P/E

Sector Avg

378.75

63.778

EPS

0.04

Dividend yield

2.19

Profit margin

-0.814

Employees

2,026

EBITDA

3.9M

45M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+32.15% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.19%

2.39%

Next Earnings

12 May 2025

Market Stats

By TradingEconomics

Market Cap

-232M

1.8B

Previous open

9.76

Previous close

9.66

News Sentiment

By Acuity

29%

71%

87 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Almirall SA Chart

Past performance is not a reliable indicator of future results.

Related News

10 Dec 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Comparison

Price change

Almirall SA Forecast

Price Target

By TipRanks

32.15% upside

12 Months Forecast

Average 13.03 EUR  32.15%

High 17 EUR

Low 10.6 EUR

Based on 4 Wall Street analysts offering 12 month price targets forAlmirall SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 10.01Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

87 / 386 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.